THINKING OUTSIDE THE BRAIN
Advancing a first of its kind approach to neurodegeneration by activating the peripheral immune system to dampen neuroinflammation in the brain
Redefining the treatment of neurodegenerative diseases
ImmunoBrain is a clinical-stage biopharmaceutical company advancing a pioneering approach to neurodegeneration – recruiting immune repairing cells to the brain that primarily address neuroinflammation, and consequentially multiple additional factors of neurodegeneration.
Alzheimer’s disease clinical trial
Phase 1b results for IBC-Ab002 demonstrated a favorable safety and tolerability profile, with early biological signals consistent with the proposed mechanism of action, supporting continued clinical development and a planned Phase 2 in Alzheimer’s
Targeting the peripheral immune system to benefit the brain
By targeting peripheral immune pathways that can be activated regardless of disease origin, ImmunoBrain’s approach may also have broader potential across multiple neurodegenerative diseases, including Parkinson’s disease, Huntington’s disease, and other forms of age-related dementia.
